DRC Receives 70,000 Ervebo Vaccine Doses to Fight Bundibugyo Virus Outbreak

The Democratic Republic of the Congo is set to receive 70,000 doses of the Ervebo vaccine through the global vaccine stockpile managed by the International Coordinating Group to combat an ongoing outbreak of the Bundibugyo virus, even though human efficacy against this specific pathogen remains unproven.

In Plain English: The Clinical Takeaway

• The Vaccine: Ervebo is officially licensed and recommended specifically for Ebola virus (formerly called Zaire ebolavirus) outbreaks, not the Bundibugyo strain currently spreading in the DRC.
• The Strategy: Out of the 70,000 doses, 20,000 are allocated for a Phase 3 clinical trial, while the remaining 50,000 will protect frontline healthcare workers.
• The Evidence: While laboratory and animal data hint at protection, human data is lacking, making informed consent critical for every recipient.

Public health authorities in the Democratic Republic of the Congo face an epidemiological challenge. According to the World Health Organization, the country will receive 70,000 doses of the Ervebo vaccine to tackle an outbreak of the Bundibugyo virus. This pathogen differs from the Ebola virus (EBOV) against which Ervebo is licensed.

One week prior, the government of the Democratic Republic of the Congo requested the release of doses of Ervebo from the global stock of vaccines against Ebola virus disease, managed by the International Coordinating Group for vaccine provision. Monday, the International Coordinating Group informed the Congolese executive of the immediate release of 70,000 doses.

This deployment involves using a vaccine against a viral species where direct clinical trial evidence in humans is still being established. Data from laboratory studies and animal models suggest that it could offer a certain level of protection against the Bundibugyo virus, but verifying this remains a priority.

Allocation, Trials, and First-Line Protection

Logistical distribution of the 70,000 doses has been divided. According to the WHO, 20,000 doses are designated for a Phase 3 clinical trial. This study will evaluate the effect of the vaccine against the Bundibugyo virus.

The remaining 50,000 doses are earmarked for the immunization of frontline workers and health personnel, in accordance with the current recommendations of the WHO’s Strategic Advisory Group of Experts on Immunization.

The WHO stresses that people offered the vaccine, inside or outside the trial, must receive information on the risks, potential benefits, and limitations related to its use during a Bundibugyo virus outbreak, and provide informed consent.

Overview of Ervebo Deployment in the Democratic Republic of the Congo

Allocation Category	Dose Count	Primary Objective
Phase 3 Clinical Trial	20,000	Evaluate the effect of the vaccine against the Bundibugyo virus.
Frontline Immunization	50,000	Immunization of frontline workers and health personnel.
Total Initial Shipment	70,000	Support response to the Bundibugyo virus outbreak.

Community Leadership and Regional Preparedness

The WHO and the Africa Centres for Disease Control and Prevention are backing a strategy in the DRC based on community leadership, which gives communities a key role in the response. The Africa CDC and the WHO reiterate their support for the Congolese government to protect affected communities and end the Ebola outbreak caused by the Bundibugyo virus, while generating the scientific data necessary to strengthen the African continent’s preparedness for future outbreaks.

References

• World Health Organization (WHO).
• Africa Centres for Disease Control and Prevention (Africa CDC).
• Strategic Advisory Group of Experts on Immunization (SAGE).
• International Coordinating Group (ICG).